Kobo Biotech's resolution plan misses 10 July deadline, no funds yet
NCLT-approved ₹70.11 crore plan from Beaufond Industries was due within 60 days. As of 14 July, terms remain unfulfilled. Monitoring committee to decide next steps.
What's new
- Court-approved resolution plan implementation delayed past 10 July 2026 deadline
- Successful resolution applicant Beaufond Industries has not completed terms as of 14 July
- Monitoring committee meeting being convened to decide next steps
Why this matters
For a company already in corporate insolvency, missing a court-set deadline for a ₹70 crore infusion is a material negative. The delay raises the risk that the resolution plan could collapse, potentially pushing Kobo toward liquidation and wiping out any residual shareholder value.
What we're watching
- Outcome of the monitoring committee meeting and any revised timeline
- Whether Beaufond can still implement the plan or if the NCLT will seek a new resolution
- Liquidation risk if the plan fails
The full read
Kobo Biotech's court-approved resolution plan hit a wall. The ₹70.11 crore infusion from Beaufond Industries was due by 10 July 2026, 60 days after the NCLT Hyderabad approved it. As of 14 July, the applicant hadn't completed the terms. The company has convened a monitoring committee to decide what comes next. For a nano-cap already in insolvency, a missed deadline on a lifeline of this size is a blow. It raises the question of whether the plan can survive — and if not, whether liquidation is the next stop. Shareholder value hangs on the committee's next move.
Questions answered
- Why did Kobo Biotech miss the resolution plan deadline?
- The company stated that the successful resolution applicant, Beaufond Industries, had not fulfilled the implementation terms as of 14 July, one day after the 10 July deadline. No specific reason was provided.
- What happens if the resolution plan is not implemented?
- The monitoring committee will decide the next steps. If the plan cannot be salvaged, the NCLT could order liquidation or invite a fresh resolution plan, further delaying any recovery for creditors and shareholders.
- How much infusion was expected under the plan?
- The plan, approved on 11 May 2026, involved a ₹70.11 crore infusion and restructuring. This was critical for Kobo, a nano-cap pharmaceutical company with a market cap of around ₹23 crore.
- What is the current financial state of Kobo Biotech?
- Kobo is undergoing corporate insolvency. Its trailing ROE is 4.3%, debt/equity is -1.09, and PAT has declined 8.4% on a trailing basis.